TY - JOUR AU - Peng, Nai-Xiong AU - Liu, Chun-Xiao AU - Wang, Xi-Sheng AU - Zhang, Ze-Jian AU - Liao, Su-Cai PY - 2015/12/25 Y2 - 2024/03/28 TI - Combination of axitinib and dasatinib for anti-cancer activities in two prostate cancer cell lines JF - Bangladesh Journal of Pharmacology JA - Bangladesh J Pharmacol VL - 11 IS - 1 SE - Research Articles DO - 10.3329/bjp.v11i1.24149 UR - https://www.banglajol.info/index.php/BJP/article/view/24149 SP - 130-137 AB - <p class="Abstract">Prostate cancer is the major cause of cancer-related deaths worldwide in men. There are new treatment methods and drugs are being developed with promising results in two of the prostate cancer cell lines (PPC-1 and TSU-Pr1). These two cells were treated with 20 uM of axitinib combined with dasatinib for 6-72 hours. The cell viability assessed by the cytotoxicity assay. Various regulatory genes such as c-KIT, cell cycle and apoptosis and angiogenic factors were also studied. The enzyme activity of apoptosis effector caspase-3 was colorimetrically determined. Axitinib and dasatinib combination lowered the survival rate of PPC-1 cells but enhanced the survival rate of TSU-Pr1 cells. The protein expression levels in apoptosis and angiogenesis factors were also found to be in contrast between the two cell lines. PPC-1 and TSU-Pr1 cells displayed a different response to axitinib with dasatinib, which explains different expression levels of regulators of cell-cycle, apoptosis and angiogenesis.</p> ER -